Skip header and navigation

Refine By

993 records – page 1 of 100.

A 3-year physical activity intervention program increases the gain in bone mineral and bone width in prepubertal girls but not boys: the prospective copenhagen school child interventions study (CoSCIS).

https://arctichealth.org/en/permalink/ahliterature91757
Source
Calcif Tissue Int. 2008 Oct;83(4):243-50
Publication Type
Article
Date
Oct-2008
Author
Hasselstrøm H A
Karlsson M K
Hansen S E
Grønfeldt V.
Froberg K.
Andersen L B
Author Affiliation
Institute for Exercise and Sport Sciences, University of Copenhagen, Copenhagen, Denmark. henrietteh62@hotmail.com
Source
Calcif Tissue Int. 2008 Oct;83(4):243-50
Date
Oct-2008
Language
English
Publication Type
Article
Keywords
Anthropometry
Bone Density - physiology
Bone Development - physiology
Bone and Bones - chemistry - physiology
Child
Denmark
Exercise
Female
Humans
Longitudinal Studies
Male
Motor Activity - physiology
Prospective Studies
Puberty - physiology
Sex Factors
Abstract
The aim of this study was to evaluate the effect of increasing the amount of time spent in physical education classes on bone mineral accrual and gain in bone size in prepubertal Danish children. A total of 135 boys and 108 girls, aged 6-8 years, were included in a school-based curriculum intervention program where the usual time spent in physical education classes was doubled to four classes (180 min) per week. The control group comprised age-matched children (62 boys and 76 girls) recruited from a separate community who completed the usual Danish school curriculum of physical activity (90 min/week). Dual-energy X-ray absorptiometry was used to evaluate bone mineral content (BMC; g), bone mineral density (g/cm(2)), and bone width at the calcaneus and distal forearm before and after 3 years of intervention. Anthropometrics and Tanner stages were evaluated on the same occasions. General physical activity was measured with an accelerometer worn for 4 days. In girls, the intervention group had a 12.5% increase (P = 0.04) in distal forearm BMC and a 13.2% increase (P = 0.005) in distal forearm scanned area compared with girls in the control group. No differences were found between the intervention and control groups in boys. Increasing the frequency of physical education classes for prepubertal children is associated with a higher accrual of bone mineral and higher gain in bone size after 3 years in girls but not in boys.
PubMed ID
18839047 View in PubMed
Less detail

A 6-year exercise program improves skeletal traits without affecting fracture risk: a prospective controlled study in 2621 children.

https://arctichealth.org/en/permalink/ahliterature259943
Source
J Bone Miner Res. 2014 Jun;29(6):1325-36
Publication Type
Article
Date
Jun-2014
Author
Fredrik Detter
Björn E Rosengren
Magnus Dencker
Mattias Lorentzon
Jan-Åke Nilsson
Magnus K Karlsson
Source
J Bone Miner Res. 2014 Jun;29(6):1325-36
Date
Jun-2014
Language
English
Publication Type
Article
Keywords
Absorptiometry, Photon
Accelerometry
Bone Density
Bone and Bones - pathology - physiopathology - radiography
Case-Control Studies
Child
Exercise - physiology
Female
Follow-Up Studies
Fractures, Bone - epidemiology - physiopathology - radiography
Humans
Kaplan-Meier Estimate
Male
Motor Activity
Prospective Studies
Risk factors
Sweden - epidemiology
Abstract
Most pediatric exercise intervention studies that evaluate the effect on skeletal traits include volunteers and follow bone mass for less than 3 years. We present a population-based 6-year controlled exercise intervention study in children with bone structure and incident fractures as endpoints. Fractures were registered in 417 girls and 500 boys in the intervention group (3969 person-years) and 835 girls and 869 boys in the control group (8245 person-years), all aged 6 to 9 years at study start, during the 6-year study period. Children in the intervention group had 40 minutes daily school physical education (PE) and the control group 60 minutes per week. In a subcohort with 78 girls and 111 boys in the intervention group and 52 girls and 54 boys in the control group, bone mineral density (BMD; g/cm(2) ) and bone area (mm(2) ) were measured repeatedly by dual-energy X-ray absorptiometry (DXA). Peripheral quantitative computed tomography (pQCT) measured bone mass and bone structure at follow-up. There were 21.7 low and moderate energy-related fractures per 1000 person-years in the intervention group and 19.3 fractures in the control group, leading to a rate ratio (RR) of 1.12 (0.85, 1.46). Girls in the intervention group, compared with girls in the control group, had 0.009?g/cm(2) (0.003, 0.015) larger gain annually in spine BMD, 0.07?g (0.014, 0.123) larger gain in femoral neck bone mineral content (BMC), and 4.1?mm(2) (0.5, 7.8) larger gain in femoral neck area, and at follow-up 24.1?g (7.6, 40.6) higher tibial cortical BMC (g) and 23.9?mm(2) (5.27, 42.6) larger tibial cross-sectional area. Boys with daily PE had 0.006?g/cm(2) (0.002, 0.010) larger gain annually in spine BMD than control boys but at follow-up no higher pQCT values than boys in the control group. Daily PE for 6 years in at study start 6- to 9-year-olds improves bone mass and bone size in girls and bone mass in boys, without affecting the fracture risk.
Notes
Comment In: J Bone Miner Res. 2014 Jun;29(6):1322-424764102
PubMed ID
24390777 View in PubMed
Less detail

The 2002 Canadian bone densitometry recommendations: take-home messages.

https://arctichealth.org/en/permalink/ahliterature187804
Source
CMAJ. 2002 Nov 12;167(10):1141-5
Publication Type
Article
Date
Nov-12-2002
Author
Aliya A Khan
Jacques P Brown
David L Kendler
William D Leslie
Brian C Lentle
E Michael Lewiecki
Paul D Miller
R Lawrence Nicholson
Wojciech P Olszynski
Nelson B Watts
Author Affiliation
Division of Geriatrics, McMaster University, Hamilton, ON. Avkhan@aol.com
Source
CMAJ. 2002 Nov 12;167(10):1141-5
Date
Nov-12-2002
Language
English
Publication Type
Article
Keywords
Bone Density
Canada
Female
Hip
Humans
Lumbar Vertebrae
Middle Aged
Osteoporosis, Postmenopausal - diagnosis
Practice Guidelines as Topic
Risk factors
Notes
Cites: Arch Intern Med. 1997 Dec 8-22;157(22):2609-159531230
Cites: Calcif Tissue Int. 1997 Dec;61(6):433-409383266
Cites: J Bone Miner Res. 1998 Oct;13(10):1587-939783547
Cites: Osteoporos Int. 1998;8 Suppl 4:S7-8010197173
Cites: JAMA. 1999 Aug 18;282(7):637-4510517716
Cites: Osteoporos Int. 1997;7 Suppl 3:S108-169536315
Cites: Osteoporos Int. 2000;11(3):192-20210824234
Cites: Am J Med. 2000 Sep;109(4):267-7610996576
Cites: J Bone Miner Res. 2000 Oct;15(10):1867-7011028437
Cites: Osteoporos Int. 2001;12(1):49-5411305083
Cites: Osteoporos Int. 2001;12(7):519-2811527048
Cites: J Clin Densitom. 2002 Fall;5(3):247-5712357062
Cites: CMAJ. 2002 Nov 12;167(10 Suppl):S1-3412427685
Cites: Ann Intern Med. 1991 Jun 1;114(11):919-232024857
Cites: J Bone Miner Res. 1992 Jun;7(6):639-461414482
Cites: Am J Epidemiol. 1993 May 1;137(9):1001-58317445
Cites: J Bone Miner Res. 1993 Oct;8(10):1227-338256660
Cites: J Bone Miner Res. 1994 Jun;9(6):951-608079669
Cites: World Health Organ Tech Rep Ser. 1994;843:1-1297941614
Cites: Osteoporos Int. 1994 Jul;4(4):226-97949753
Cites: N Engl J Med. 1995 Mar 23;332(12):767-737862179
Cites: J Orthop Res. 1995 Mar;13(2):250-77722762
Cites: Bone. 1995 Apr;16(4 Suppl):257S-262S7626313
Cites: Osteoporos Int. 1995;5(4):262-707492865
Cites: N Engl J Med. 1995 Nov 30;333(22):1437-437477143
Cites: BMJ. 1996 May 18;312(7041):1254-98634613
Cites: Bone. 1996 Mar;18(3 Suppl):197S-201S8777088
Cites: Lancet. 1996 Aug 24;348(9026):511-48757153
Cites: N Engl J Med. 1997 Sep 4;337(10):670-69278463
Comment In: CMAJ. 2003 Jan 21;168(2):14912538531
PubMed ID
12427706 View in PubMed
Less detail

2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.

https://arctichealth.org/en/permalink/ahliterature187810
Source
CMAJ. 2002 Nov 12;167(10 Suppl):S1-34
Publication Type
Article
Date
Nov-12-2002
Author
Jacques P Brown
Robert G Josse
Author Affiliation
Division of Rheumatology, Centre de recherche du CHUL, Université Laval, Canada.
Source
CMAJ. 2002 Nov 12;167(10 Suppl):S1-34
Date
Nov-12-2002
Language
English
Publication Type
Article
Keywords
Adult
Aged
Bone Density
Canada
Child
Diet
Diphosphonates - therapeutic use
Estrogens, Non-Steroidal
Female
Humans
Isoflavones
Male
Middle Aged
Osteoporosis - diagnosis - drug therapy - prevention & control
Phytoestrogens
Plant Preparations
Practice Guidelines as Topic
Prognosis
Randomized Controlled Trials as Topic
Risk factors
Abstract
To revise and expand the 1996 Osteoporosis Society of Canada clinical practice guidelines for the management of osteoporosis, incorporating recent advances in diagnosis, prevention and management of osteoporosis, and to identify and assess the evidence supporting the recommendations.
All aspects of osteoporosis care and its fracture complications - including classification, diagnosis, management and methods for screening, as well as prevention and reducing fracture risk - were reviewed, revised as required and expressed as a set of recommendations.
Strategies for identifying and evaluating those at high risk; the use of bone mineral density and biochemical markers in diagnosis and assessing response to management; recommendations regarding nutrition and physical activity; and the selection of pharmacologic therapy for the prevention and management of osteoporosis in men and women and for osteoporosis resulting from glucocorticoid treatment.
All recommendations were developed using a justifiable and reproducible process involving an explicit method for the evaluation and citation of supporting evidence.
All recommendations were reviewed by members of the Scientific Advisory Council of the Osteoporosis Society of Canada, an expert steering committee and others, including family physicians, dietitians, therapists and representatives of various medical specialties involved in osteoporosis care (geriatric medicine, rheumatology, endocrinology, obstetrics and gynecology, nephrology, radiology) as well as methodologists from across Canada.
Earlier diagnosis and prevention of fractures should decrease the medical, social and economic burdens of this disease.
This document outlines detailed recommendations pertaining to all aspects of osteoporosis. Strategies for identifying those at increased risk (i.e., those with at least one major or 2 minor risk factors) and screening with central dual-energy x-ray absorptiometry at age 65 years are recommended. Bisphosphonates and raloxifene are first-line therapies in the prevention and treatment of postmenopausal osteoporosis. Estrogen and progestin/progesterone is a first-line therapy in the prevention and a second-line therapy in the treatment of postmenopausal osteoporosis. Nasal calcitonin is a second-line therapy in the treatment of postmenopausal osteoporosis. Although not yet approved for use in Canada, hPTH(1-34) is expected to be a first-line treatment for postmenopausal women with severe osteoporosis. Ipriflavone, vitamin K and fluoride are not recommended. Bisphosphonates are the first-line therapy for the prevention and treatment of osteoporosis in patients requiring prolonged glucocorticoid therapy and for men with osteoporosis. Nasal or parenteral calcitonin is a first-line treatment for pain associated with acute vertebral fractures. Impact-type exercise and age-appropriate calcium and vitamin D intake are recommended for the prevention of osteoporosis.
All recommendations were graded according to the strength of the evidence; where the evidence was insufficient and recommendations were based on consensus opinion alone, this is indicated. These guidelines are viewed as a work in progress and will be updated periodically in response to advances in this field.
Notes
Cites: J Clin Endocrinol Metab. 2000 May;85(5):1895-90010843171
Cites: Bone. 2000 Jul;27(1):123-810865219
Cites: J Bone Miner Res. 2000 Jul;15(7):1398-40410893690
Cites: Calcif Tissue Int. 2000 Jul;67(1):10-810908406
Cites: N Engl J Med. 2000 Aug 31;343(9):604-1010979796
Cites: Osteoporos Int. 2000;11(6):467-8010982161
Cites: J Clin Endocrinol Metab. 2000 Sep;85(9):3069-7610999788
Cites: Am J Med. 2000 Sep;109(4):267-7610996576
Cites: Calcif Tissue Int. 2000 Oct;67(4):277-8511000340
Cites: BMJ. 2000 Oct 21;321(7267):994-811039967
Cites: Spine (Phila Pa 1976). 1992 Mar;17(3):280-51566165
Cites: Calcif Tissue Int. 1992 Apr;50(4):381-31571851
Cites: Bone Miner. 1992 Feb;16(2):131-81576488
Cites: Ann Intern Med. 1992 Jul 1;117(1):1-91534476
Cites: J Nucl Med. 1992 Jun;33(6):1137-421597729
Cites: N Engl J Med. 1992 Jul 9;327(2):82-71603140
Cites: Calcif Tissue Int. 1991 Dec;49(6):369-721818759
Cites: J Bone Miner Res. 1992 Jul;7(7):761-91642145
Cites: BMJ. 1992 Sep 5;305(6853):556-611393035
Cites: J Appl Physiol (1985). 1992 Sep;73(3):1165-701400032
Cites: J Bone Miner Res. 1992 Sep;7(9):1005-101414493
Cites: Med Sci Sports Exerc. 1992 Nov;24(11):1190-41435170
Cites: N Engl J Med. 1992 Dec 3;327(23):1637-421331788
Cites: Maturitas. 1992 Dec;15(3):225-321465036
Cites: Lancet. 1993 Jan 9;341(8837):72-58093403
Cites: N Engl J Med. 1993 Feb 18;328(7):460-48421475
Cites: Osteoporos Int. 1993 Mar;3(2):71-58453193
Cites: Bone Miner. 1993 Feb;20(2):125-328453328
Cites: Calcif Tissue Int. 1993 Mar;52(3):212-58481835
Cites: Am J Med. 1993 Jun;94(6):646-508506892
Cites: Am J Epidemiol. 1993 May 1;137(9):1001-58317445
Cites: Br J Radiol. 1993 May;66(785):435-408319065
Cites: J Endocrinol Invest. 1993 May;16(5):333-78320424
Cites: Osteoporos Int. 1993 Jul;3(4):185-918338973
Cites: CMAJ. 1993 Aug 1;149(3):289-938339174
Cites: JAMA. 1993 Aug 18;270(7):841-48340983
Cites: J Clin Endocrinol Metab. 1993 Sep;77(3):770-58370698
Cites: Osteoporos Int. 1993 Sep;3(5):255-608400607
Cites: J Bone Miner Res. 1993 Aug;8(8):931-68213255
Cites: Calcif Tissue Int. 1999 Nov;65(5):359-6410541760
Cites: Osteoporos Int. 1999;9(4):296-30610550446
Cites: Osteoporos Int. 1999;9(4):358-6610550454
Cites: Osteoporos Int. 1999;9(5):461-810550467
Cites: Arthritis Rheum. 1999 Nov;42(11):2309-1810555025
Cites: J Bone Miner Res. 1999 Nov;14(11):1952-6210571696
Cites: J Am Geriatr Soc. 1999 Dec;47(12):1397-40210591231
Cites: Ann Intern Med. 1999 Dec 21;131(12):935-4210610644
Cites: Arterioscler Thromb Vasc Biol. 1999 Dec;19(12):2993-300010591680
Cites: Am J Clin Nutr. 2000 Jan;71(1):142-5110617959
Cites: Int J Clin Pract. 1998 Oct;52(7):453-510622084
Cites: Osteoporos Int. 1999;10(3):183-9210525709
Cites: J Clin Densitom. 2000 Spring;3(1):27-3310745299
Cites: J Bone Miner Res. 2000 Mar;15(3):515-2110750566
Cites: Ann Intern Med. 2000 May 2;132(9):689-9610787361
Cites: Am J Clin Nutr. 1986 Dec;44(6):863-763491533
Cites: Am J Clin Nutr. 1987 Aug;46(2):319-233618535
Cites: Eur J Clin Pharmacol. 1987;33(1):35-93319638
Cites: Lancet. 1987 Dec 26;2(8574):1481-32892047
Cites: Acta Paediatr Scand. 1988 Jan;77(1):89-933285637
Cites: Am J Clin Nutr. 1988 Sep;48(3 Suppl):842-93414592
Cites: J Bone Miner Res. 1986 Aug;1(4):377-813503551
Cites: Lancet. 1988 Nov 5;2(8619):1046-92903278
Cites: Bone Miner. 1988 Jul;4(3):265-773191284
Cites: BMJ. 1988 Dec 3;297(6661):1441-33147007
Cites: Age Ageing. 1988 Sep;17(5):319-273232586
Cites: BMJ. 1989 Jan 21;298(6667):147-512538173
Cites: Med Sci Sports Exerc. 1989 Feb;21(1):66-702927303
Cites: Br J Cancer. 1989 Mar;59(3):445-72930713
Cites: J Bone Miner Res. 1989 Apr;4(2):223-52728925
Cites: Clin Ther. 1989 Mar-Apr;11(2):205-92660996
Cites: Drugs Exp Clin Res. 1989;15(2):97-1042661184
Cites: Mayo Clin Proc. 1989 Jul;64(7):762-92671517
Cites: BMJ. 1989 Aug 19;299(6697):477-92507027
Cites: Eur J Appl Physiol Occup Physiol. 1993;67(4):330-48299600
Cites: Radiology. 1994 Mar;190(3):678-828115610
Cites: Osteoporos Int. 1994 Jan;4(1):1-58148565
Cites: J Bone Miner Res. 1994 Jan;9(1):69-738154311
Cites: Br J Rheumatol. 1994 Apr;33(4):348-508156307
Cites: BMJ. 1994 Apr 23;308(6936):1081-28173430
Cites: Minerva Endocrinol. 1993 Sep;18(3):115-218183178
Cites: Am J Respir Crit Care Med. 1994 Aug;150(2):394-78049820
Cites: Lancet. 1994 Aug 20;344(8921):543-47914635
Cites: Calcif Tissue Int. 1994 May;54(5):377-808062153
Cites: Osteoporos Int. 2000;11(7):556-6111069188
Cites: J Clin Densitom. 2000 Fall;3(3):269-8011090234
Cites: Osteoporos Int. 2000;11(8):709-1311095175
Cites: J Clin Endocrinol Metab. 2000 Nov;85(11):4118-2411095442
Cites: J Bone Miner Res. 2000 Dec;15(12):2309-1411127196
Cites: N Engl J Med. 2001 Feb 1;344(5):333-4011172164
Cites: Arthritis Rheum. 2001 Jan;44(1):202-1111212161
Cites: JAMA. 2001 Jan 17;285(3):320-311176842
Cites: J Orthop Sci. 2000;5(6):546-5111180916
Cites: Osteoporos Int. 2000;11(12):1018-2311256892
Cites: Osteoporos Int. 2000;11(12):1051-6211256897
Cites: JAMA. 2001 Mar 21;285(11):1482-811255425
Cites: Ann Intern Med. 1989 Oct 15;111(8):678-802679286
Cites: Arch Intern Med. 1989 Oct;149(10):2197-2002802886
Cites: Arch Intern Med. 1989 Nov;149(11):2445-82818106
Cites: Clin Endocrinol (Oxf). 1989 Apr;30(4):435-422688995
Cites: J Clin Endocrinol Metab. 1990 Jan;70(1):264-702294135
Cites: JAMA. 1990 Feb 2;263(5):665-82404146
Cites: N Engl J Med. 1990 Mar 22;322(12):802-92407957
Cites: Br J Ind Med. 1990 Jan;47(1):69-702310712
Cites: N Engl J Med. 1990 May 3;322(18):1265-712109197
Cites: N Engl J Med. 1990 Jul 12;323(2):73-92113611
Cites: Age Ageing. 1990 May;19(3):212-42363385
Cites: Am Rev Respir Dis. 1990 Jul;142(1):104-72195929
Cites: J Bone Miner Res. 2000 Apr;15(4):710-2010780863
Cites: J Bone Miner Res. 2000 Apr;15(4):721-3910780864
Cites: J Bone Miner Res. 2000 May;15(5):944-5110804025
Cites: CMAJ. 2000 May 2;162(9):1289-9410813010
Cites: Osteoporos Int. 2000;11(3):192-20210824234
Cites: J Bone Miner Res. 2000 Jun;15(6):993-100010841167
Cites: J Bone Miner Res. 2000 Jun;15(6):1006-1310841169
Cites: J Clin Endocrinol Metab. 2000 May;85(5):1783-810843152
Cites: Arch Intern Med. 1991 Oct;151(10):2026-321929691
Cites: Calcif Tissue Int. 1991;49 Suppl:S83-41834319
Cites: J Bone Miner Res. 1991 Nov;6(11):1227-331805545
Cites: J Bone Miner Res. 1995 Jun;10(6):940-77572318
Cites: Int J Epidemiol. 1995 Aug;24(4):771-828550275
Cites: J Bone Miner Res. 1995 Sep;10(9):1303-117502701
Cites: J Bone Miner Res. 1995 Sep;10(9):1312-207502702
Cites: Osteoporos Int. 1995;5(4):218-277492859
Cites: Osteoporos Int. 1995;5(4):262-707492865
Cites: Am J Clin Nutr. 1995 Oct;62(4):740-57572702
Cites: N Engl J Med. 1995 Nov 30;333(22):1437-437477143
Cites: J Bone Miner Res. 1995 Jul;10(7):1068-757484282
Cites: Bone. 1995 Oct;17(4):383-908573412
Cites: J Am Geriatr Soc. 1996 May;44(5):489-978617895
Cites: Calcif Tissue Int. 1996 Feb;58(2):73-808998681
Cites: BMJ. 1996 May 18;312(7041):1254-98634613
Cites: Osteoporos Int. 1995;5(6):462-68695969
Cites: Osteoporos Int. 1995;5(6):467-718695970
Cites: J Bone Miner Res. 1996 Apr;11(4):490-5018992880
Cites: J Am Geriatr Soc. 1996 Jul;44(7):756-628675921
Cites: Calcif Tissue Int. 1996 Jun;58(6):398-4018661479
Cites: Calcif Tissue Int. 1996 Jul;59(1):6-118661976
Cites: Osteoporos Int. 1996;6(2):171-78704358
Cites: Lancet. 1996 Jul 20;348(9021):145-98684153
Cites: Am J Epidemiol. 1996 Aug 1;144(3):255-638686694
Cites: Am J Obstet Gynecol. 1996 Jul;175(1):105-98694034
Cites: Biomed Pharmacother. 1995;49(10):465-88746073
Cites: Lancet. 1996 Aug 24;348(9026):511-48757153
Cites: N Engl J Med. 1996 Oct 3;335(14):1069-708801453
Cites: Bone. 1996 Jun;18(6):629-328806006
Cites: Miner Electrolyte Metab. 1996;22(4):207-138807623
Cites: Osteoporos Int. 1996;6(1):8-138845604
Cites: Med Sci Sports Exerc. 1993 Oct;25(10):1103-98231753
Cites: Am J Med. 1993 Dec;95(6):557-678259772
Cites: Calcif Tissue Int. 1993 Nov;53(5):307-118287317
Cites: Breast Cancer Res Treat. 2001 Jan;65(2):125-3411261828
Cites: BMJ. 2001 Mar 24;322(7288):697-70111264206
Cites: Osteoporos Int. 2001;12(2):85-9011303719
Cites: N Engl J Med. 2001 May 10;344(19):1434-4111346808
Cites: Climacteric. 2001 Mar;4(1):58-7411379379
Cites: JAMA. 2001 Jul 4;286(1):57-6311434827
Cites: NIH Consens Statement. 2000 Mar 27-29;17(1):1-4511525451
Cites: Calcif Tissue Int. 2001 Aug;69(2):73-711683426
Cites: Calcif Tissue Int. 2001 Oct;69(4):242-711730260
Cites: J Clin Densitom. 2001 Winter;4(4):363-7111748341
Cites: J Bone Miner Res. 2002 Jan;17(1):11-411771656
Cites: Eur J Clin Nutr. 2001 Dec;55(12):1091-711781676
Cites: J Orthop Sci. 2001;6(6):487-9211793169
Cites: Osteoporos Int. 2001 Dec;12(12):989-9511846333
Cites: JAMA. 2002 Feb 20;287(7):847-5711851576
Cites: Br J Sports Med. 2002 Feb;36(1):10-311867483
Cites: J Bone Miner Res. 2002 Mar;17(3):363-7211874228
Cites: J Bone Miner Res. 2002 May;17(5):834-4412009014
Cites: Arch Intern Med. 2002 May 27;162(10):1140-312020184
Cites: J Bone Miner Res. 2002 Jun;17(6):1051-612054160
Cites: CMAJ. 2002 May 28;166(11):1426-3012054412
Cites: Osteoporos Int. 1999;10(3):214-2110525713
Cites: Osteoporos Int. 2000;11(1):83-9110663363
Cites: J Clin Endocrinol Metab. 2000 Feb;85(2):720-610690882
Cites: Br J Sports Med. 2000 Feb;34(1):18-2210690445
Cites: Semin Arthritis Rheum. 2000 Feb;29(4):228-5110707991
Cites: BMJ. 2000 Mar 18;320(7237):754-810720360
Cites: Arch Intern Med. 2000 Mar 13;160(5):705-810724057
Cites: Aging (Milano). 2000 Feb;12(1):1-1210746426
Cites: Epidemiol Rev. 1985;7:178-2083902494
Cites: Am J Clin Nutr. 1985 Nov;42(5):877-883877451
Cites: Acta Obstet Gynecol Scand. 1986;65(3):211-73739627
Cites: Calcif Tissue Int. 1997 Jul;61(1):39-439192511
Cites: J Bone Miner Res. 1997 Jul;12(7):1075-829200007
Cites: Am J Med. 1997 Jan;102(1):29-379209198
Cites: Ann Rheum Dis. 1997 Jun;56(6):357-639227164
Cites: N Engl J Med. 1997 Aug 7;337(6):382-79241127
Cites: Calcif Tissue Int. 1997 Aug;61(2):142-79236262
Cites: N Engl J Med. 1997 Aug 21;337(8):523-89262495
Cites: N Engl J Med. 1997 Sep 4;337(10):670-69278463
Cites: Age Ageing. 1997 Jul;26(4):253-609271287
Cites: Am J Med. 1997 Aug;103(2):92-99274891
Cites: BMJ. 1997 Aug 2;315(7103):305-89274555
Cites: J Clin Endocrinol Metab. 1997 Sep;82(9):2784-919284696
Cites: Lancet. 1997 Aug 23;350(9077):550-59284777
Cites: J Bone Miner Res. 1997 Sep;12(9):1453-629286762
Cites: J Bone Miner Res. 1997 Sep;12(9):1463-709286763
Cites: Br J Nutr. 1997 Jul;78(1):65-729292760
Cites: Am J Clin Nutr. 1997 Oct;66(4):867-739322562
Cites: Age Ageing. 1997 Sep;26(5):359-659351480
Cites: BMJ. 1997 Oct 25;315(7115):1065-99366737
Cites: Calcif Tissue Int. 1997 Nov;61(5):382-59351879
Cites: N Engl J Med. 1997 Dec 4;337(23):1641-79385122
Cites: CMAJ. 1997 Nov 15;157(10):1357-639371065
Cites: Osteoporos Int. 1997;7(4):331-79373566
Cites: J Bone Miner Res. 1997 Nov;12(11):1761-89383679
Cites: Acta Orthop Scand Suppl. 1997 Oct;275:108-119385282
Cites: Acta Orthop Scand Suppl. 1997 Oct;275:112-49385283
Cites: Maturitas. 1997 Sep;28(1):75-819391998
Cites: Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):14105-109391160
Cites: Osteoporos Int. 1997;7(5):488-959425508
Cites: Bone. 1994 May-Jun;15(3):279-848068448
Cites: N Engl J Med. 1994 Sep 29;331(13):821-78078528
Cites: J Bone Miner Res. 1994 Jun;9(6):951-608079669
Cites: Agents Actions. 1994 Mar;41(1-2):86-78079827
Cites: Calcif Tissue Int. 1994 Jun;54(6):477-808082050
Cites: World Health Organ Tech Rep Ser. 1994;843:1-1297941614
Cites: Am J Clin Nutr. 1994 Nov;60(5):744-507619105
Cites: Calcif Tissue Int. 1994 Aug;55(2):82-67953984
Cites: J Clin Endocrinol Metab. 1994 Oct;79(4):950-47962303
Cites: J Bone Miner Res. 1994 Aug;9(8):1137-417976495
Cites: Eur J Clin Invest. 1994 Aug;24(8):565-97982445
Cites: JAMA. 1994 Dec 28;272(24):1909-147990242
Cites: Osteoporos Int. 1994 Sep;4(5):245-527812072
Cites: J Bone Miner Res. 1994 Oct;9(10):1503-147817795
Cites: J Bone Miner Res. 1994 Oct;9(10):1591-57817805
Cites: Thorax. 1994 Nov;49(11):1099-1027831624
Cites: N Engl J Med. 1995 Mar 23;332(12):767-737862179
Cites: J Gerontol A Biol Sci Med Sci. 1995 Mar;50(2):B97-1047874586
Cites: Fertil Steril. 1995 Apr;63(4):747-557890057
Cites: J Pediatr. 1995 Apr;126(4):551-67699532
Cites: Osteoporos Int. 1995 Jan;5(1):39-467703623
Cites: Am J Med. 1995 Apr;98(4):331-57709944
Cites: Am J Med. 1995 May;98(5):452-87733123
Cites: Calcif Tissue Int. 1995 Mar;56(3):181-57750020
Cites: N Engl J Med. 1990 Sep 27;323(13):878-832203964
Cites: Am J Epidemiol. 1990 Oct;132(4):675-842403108
Cites: Bone. 1990;11(4):229-322242288
Cites: Ann Intern Med. 1991 Jun 1;114(11):919-232024857
Cites: Calcif Tissue Int. 1991 May;48(5):302-72054714
Cites: Am J Clin Nutr. 1991 Jul;54(1):157-632058578
Cites: Ann Intern Med. 1991 Oct 1;115(7):505-121883119
Cites: J Bone Miner Res. 1991 Jun;6(6):583-901887821
Cites: Ann Intern Med. 1995 Sep 15;123(6):401-87639438
Cites: Am J Med. 1995 Sep;99(3):235-427653482
Cites: Br J Nutr. 1995 Jul;74(1):125-397547823
Cites: Transplantation. 1998 Oct 27;66(8):1004-89808483
Cites: CMAJ. 1998;159 Suppl 8:S1-299834731
Cites: Radiol Technol. 1998 Nov-Dec;70(2):224, 2239839336
Cites: J Bone Miner Res. 1998 Dec;13(12):1814-219844098
Cites: J Bone Miner Res. 1998 Dec;13(12):1915-239844110
Cites: J Bone Miner Res. 1998 Dec;13(12):1932-99844112
Cites: JAMA. 1998 Dec 23-30;280(24):2077-829875874
Cites: J Bone Miner Res. 1999 Jan;14(1):90-1019893070
Cites: Calcif Tissue Int. 1999 Feb;64(2):179-839914328
Cites: Am J Clin Nutr. 1999 Jan;69(1):74-99925126
Cites: Am J Clin Nutr. 1999 Jan;69(1):147-529925137
Cites: Lancet. 1999 Jan 9;353(9147):93-710023893
Cites: Calcif Tissue Int. 1999 Mar;64(3):200-410024375
Cites: Osteoporos Int. 1998;8(4):333-4010024903
Cites: Ann Rheum Dis. 1998 Dec;57(12):724-710070271
Cites: Bone. 1999 Mar;24(3):261-410071920
Cites: Lancet. 1999 Mar 13;353(9156):878-8210093980
Cites: Osteoporos Int. 1998;8 Suppl 4:S7-8010197173
Cites: Obstet Gynecol. 1999 Apr;93(4):558-6510214833
Cites: Maturitas. 1999 Jan 4;31(2):161-410227010
Cites: J Bone Miner Res. 1999 May;14(5):821-810320531
Cites: Osteoporos Int. 1998;8(6):563-910326062
Cites: Med Sci Sports Exerc. 1999 May;31(5):646-5210331882
Cites: Rev Rhum Engl Ed. 1999 Apr;66(4):214-910339777
Cites: Calcif Tissue Int. 1999 Jun;64(6):490-810341021
Cites: Osteoporos Int. 1999;9(1):1-1210367023
Cites: Osteoporos Int. 1999;9(2):188-9210367048
Cites: Ann Intern Med. 1999 Jun 1;130(11):897-90410375338
Cites: JAMA. 1999 Jun 16;281(23):2189-9710376571
Cites: J Bone Miner Res. 1996 Feb;11(2):218-258822346
Cites: J Bone Miner Res. 1996 Feb;11(2):293-78822354
Cites: Bone. 1996 Feb;18(2):141-508833208
Cites: Bone. 1996 Feb;18(2):207-128833216
Cites: CMAJ. 1996 Oct 1;155(7):921-38837540
Cites: J Bone Miner Res. 1996 Mar;11(3):337-498852944
Cites: CMAJ. 1996 Oct 15;155(8):1113-338873639
Cites: Osteoporos Int. 1996;6(4):276-838883115
Cites: Osteoporos Int. 1996;6(4):303-78883119
Cites: Osteoporos Int. 1996;6(4):308-138883120
Cites: J Bone Miner Res. 1996 Oct;11(10):1531-88889854
Cites: JAMA. 1996 Nov 6;276(17):1389-968892713
Cites: Med Sci Sports Exerc. 1996 Oct;28(10):1243-68897380
Cites: J Gerontol A Biol Sci Med Sci. 1996 Nov;51(6):B425-338914492
Cites: J Rheumatol. 1996 Nov;23(11):1875-98923359
Cites: Osteoporos Int. 1996;6(5):399-4068931035
Cites: Am J Med. 1996 Nov;101(5):488-5018948272
Cites: Lancet. 1996 Dec 7;348(9041):1535-418950879
Cites: J Bone Miner Res. 1996 Dec;11(12):1961-68970899
Cites: Can J Physiol Pharmacol. 1996 Oct;74(10):1180-59022839
Cites: J Clin Endocrinol Metab. 1997 Feb;82(2):620-89024265
Cites: Osteoporos Int. 1996;6(6):437-419116388
Cites: Clin Sci (Lond). 1997 Jan;92(1):75-809038595
Cites: J Hepatol. 1997 Feb;26(2):325-309059953
Cites: Mayo Clin Proc. 2002 Jul;77(7):629-3712108600
Cites: JAMA. 2002 Jul 17;288(3):321-3312117397
Cites: Calcif Tissue Int. 2002 Aug;71(2):103-1112085156
Cites: J Lab Clin Med. 1971 Dec;78(6):994-55131875
Cites: Br Med J. 1980 Jun 7;280(6228):1340-46992932
Cites: J Clin Endocrinol Metab. 1981 Apr;52(4):751-86970749
Cites: Lancet. 1984 Aug 4;2(8397):2836146829
Cites: South Med J. 1984 Dec;77(12):1509-156505760
Cites: Osteoporos Int. 1997;7(2):126-329166392
Cites: J Clin Endocrinol Metab. 1997 Jun;82(6):1904-109177404
Cites: Calcif Tissue Int. 1997 Jul;61(1):10-59192504
Cites: Ann Intern Med. 1998 Feb 15;128(4):253-619471927
Cites: N Engl J Med. 1998 Feb 19;338(8):485-929443925
Cites: Bone. 1998 Feb;22(2):147-519477238
Cites: J Bone Miner Res. 1998 Feb;13(2):168-749495509
Cites: J Bone Miner Res. 1998 Feb;13(2):303-99495525
Cites: Maturitas. 1997 Dec 15;28(2):147-519522322
Cites: J Bone Miner Res. 1998 Mar;13(3):483-909525349
Cites: J Clin Endocrinol Metab. 1998 Apr;83(4):1128-339543129
Cites: Am J Med. 1998 Mar;104(3):219-269552083
Cites: Calcif Tissue Int. 1998 Jun;62(6):491-69576975
Cites: JAMA. 1998 May 13;279(18):1445-519600478
Cites: Osteoporos Int. 1997;7(6):575-829604055
Cites: J Bone Miner Res. 1998 Jun;13(6):918-249626622
Cites: Ann Intern Med. 1998 Jul 1;129(1):1-89652994
Cites: J Bone Miner Res. 1998 Jul;13(7):1141-89661078
Cites: J Bone Miner Res. 1998 Jul;13(7):1149-579661079
Cites: J Clin Endocrinol Metab. 1998 Jul;83(7):2266-749661593
Cites: Clin Endocrinol (Oxf). 1998 May;48(5):655-629666879
Cites: Osteoporos Int. 1998;8(2):152-89666939
Cites: N Engl J Med. 1998 Jul 30;339(5):292-99682041
Cites: Menopause. 1998 Spring;5(1):9-159689189
Cites: Osteoporos Int. 1998;8(1):4-129692071
Cites: Osteoporos Int. 1998;8(1):47-529692077
Cites: Endocr J. 1998 Apr;45(2):191-2019700472
Cites: Thorax. 1998 May;53(5):351-69708225
Cites: Endocr Rev. 1998 Aug;19(4):397-4289715373
Cites: JAMA. 1998 Aug 19;280(7):605-139718051
Cites: JAMA. 1998 Aug 19;280(7):650-29718060
Cites: Int J Gynaecol Obstet. 1998 Jul;62(1):69-759722129
Cites: J Bone Miner Res. 1998 Sep;13(9):1431-89738515
Cites: J Natl Cancer Inst. 1998 Sep 16;90(18):1371-889747868
Cites: Am J Clin Nutr. 1998 Oct;68(4):854-89771862
Cites: J Bone Miner Res. 1998 Oct;13(10):1587-939783547
Cites: J Clin Invest. 1998 Oct 15;102(8):1627-339788977
Cites: Osteoporos Int. 1998;8(3):255-609797910
Cites: Scand J Rheumatol. 1999;28(3):152-610380836
Cites: Clin Chem. 1999 Jul;45(7):1009-1710388477
Cites: J Clin Endocrinol Metab. 1999 Jul;84(7):2349-5210404801
Cites: J Am Geriatr Soc. 1999 Jul;47(7):850-310404930
Cites: Bone. 1999 Jul;25(1):97-10610423031
Cites: J Clin Endocrinol Metab. 1999 Aug;84(8):2700-410443663
Cites: J Bone Miner Res. 1999 Aug;14(8):1387-9310457271
Cites: J Bone Miner Res. 1999 Aug;14(8):1449-5610457279
Cites: J Bone Miner Res. 1999 Sep;14(9):1614-2110469291
Cites: Obstet Gynecol. 1999 Sep;94(3):330-610472854
Cites: Horm Res. 1999;51(4):178-8310474019
Cites: Cancer Causes Control. 1999 Aug;10(4):253-6010482483
Cites: J Clin Endocrinol Metab. 1999 Sep;84(9):3076-8110487668
Cites: Menopause. 1999 Fall;6(3):233-4110486794
Cites: J Bone Miner Res. 1999 Oct;14(10):1672-910491214
Cites: JAMA. 1999 Aug 18;282(7):637-4510517716
Cites: JAMA. 1999 Oct 13;282(14):1344-5210527181
Cites: J Clin Invest. 1964 Apr;43:545-5514149908
Cites: Int J Gynaecol Obstet. 1995 Mar;48(3):283-87781871
Cites: Bone. 1995 Mar;16(3):325-327786635
Cites: Calcif Tissue Int. 1995 Jan;56(1):38-417796344
Cites: Am J Clin Nutr. 1995 Jul;62(1):58-677598067
Cites: Am J Med. 1995 Jul;99(1):36-427598140
Cites: Bone. 1995 Apr;16(4):469-767605708
Cites: J Bone Miner Res. 1995 Apr;10(4):586-937610929
Cites: Am J Med. 1995 Aug;99(2):144-527625419
Cites: J Clin Oncol. 1997 Mar;15(3):955-629060533
Cites: Ann Med. 1997 Feb;29(1):55-629073324
Cites: Osteoporos Int. 1997;7(1):29-359102059
Cites: J Clin Invest. 1997 Mar 15;99(6):1287-949077538
Cites: Arch Intern Med. 1997 Mar 24;157(6):629-349080917
Cites: J Bone Miner Res. 1997 Apr;12(4):509-219101362
Cites: Br J Rheumatol. 1997 Feb;36(2):255-99133941
Cites: Osteoporos Int. 1997;7(2):119-259166391
Comment In: CMAJ. 2007 Oct 23;177(9):1069; author reply 1069-7017954901
Comment In: CMAJ. 2003 Jun 24;168(13):1644-5; author reply 1645-612821610
Comment In: CMAJ. 2003 Mar 18;168(6):675-6; author reply 67612642419
Comment In: CMAJ. 2003 Mar 18;168(6):67212642415
Comment In: CMAJ. 2003 Jun 24;168(13):1644; author reply 1645-612821611
Erratum In: CMAJ. 2003 Mar 18;168(6):676.
Erratum In: CMAJ. 2003 Mar 4;168(5):544
Erratum In: CMAJ. 2003 Feb 18;168(4):400
PubMed ID
12427685 View in PubMed
Less detail

2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary.

https://arctichealth.org/en/permalink/ahliterature140116
Source
CMAJ. 2010 Nov 23;182(17):1864-73
Publication Type
Article
Date
Nov-23-2010
Author
Alexandra Papaioannou
Suzanne Morin
Angela M Cheung
Stephanie Atkinson
Jacques P Brown
Sidney Feldman
David A Hanley
Anthony Hodsman
Sophie A Jamal
Stephanie M Kaiser
Brent Kvern
Kerry Siminoski
William D Leslie
Author Affiliation
Department of Medicine, Division of Geriatrics, McMaster University, Hamilton, Ont. papaioannou@hhsc.ca
Source
CMAJ. 2010 Nov 23;182(17):1864-73
Date
Nov-23-2010
Language
English
Publication Type
Article
Keywords
Accidental Falls - prevention & control
Age Factors
Bone Density
Bone Density Conservation Agents - adverse effects - therapeutic use
Calcium - therapeutic use
Canada
Dietary Supplements
Exercise Therapy
Female
Humans
Male
Middle Aged
Osteoporosis - diagnosis - therapy
Osteoporotic Fractures - prevention & control
Risk factors
Vitamin D - therapeutic use
Notes
Cites: Lancet. 2007 Aug 25;370(9588):657-6617720017
Cites: Osteoporos Int. 2007 Nov;18(11):1463-7217726622
Cites: J Bone Miner Res. 2007 Oct;22(10):1479-9117663640
Cites: Arch Intern Med. 2007 Oct 22;167(19):2110-517954806
Cites: N Engl J Med. 2007 Nov 1;357(18):1799-80917878149
Cites: Osteoporos Int. 2008 Jan;19(1):79-8617641811
Cites: J Am Dent Assoc. 2008 Jan;139(1):32-4018167382
Cites: J Bone Miner Res. 2009 Feb;24(2):353-6019514851
Cites: Clin Biochem. 2009 Jul;42(10-11):929-4219362543
Cites: N Engl J Med. 2009 Aug 20;361(8):756-6519671655
Cites: N Engl J Med. 2009 Aug 20;361(8):745-5519671656
Cites: CMAJ. 2009 Sep 1;181(5):265-7119654194
Cites: Clin Rehabil. 2009 Oct;23(10):888-9619717503
Cites: J Bone Miner Res. 2009 Nov;24(11):1800-719419321
Cites: CMAJ. 2009 Nov 24;181(11):815-2019841053
Cites: Osteoporos Int. 2008 Mar;19(3):365-7217938986
Cites: Ann Intern Med. 2008 Feb 5;148(3):197-21318087050
Cites: Osteoporos Int. 2008 Apr;19(4):581-717924051
Cites: Osteoporos Int. 2008 Apr;19(4):437-4718292976
Cites: JAMA. 2008 Mar 26;299(12):1468-7018364489
Cites: Osteoporos Int. 2008 Aug;19(8):1119-2318286218
Cites: Osteoporos Int. 2008 Oct;19(10):1363-818546030
Cites: Cochrane Database Syst Rev. 2000;(2):CD00198310796457
Cites: JAMA. 2001 Jan 17;285(3):320-311176842
Cites: Osteoporos Int. 2001;12(4):271-811420776
Cites: J Clin Endocrinol Metab. 2002 Mar;87(3):985-9211889149
Cites: Osteoporos Int. 2008 Oct;19(10):1395-40818751937
Cites: Ann Intern Med. 2008 Sep 16;149(6):404-1518794560
Cites: J Clin Oncol. 2008 Oct 20;26(30):4875-8218725648
Cites: CMAJ. 2008 Oct 21;179(9):901-818936455
Cites: Ann Epidemiol. 2008 Nov;18(11):827-3518809340
Cites: J Gen Intern Med. 2008 Dec;23(12):2095-10518836782
Cites: N Engl J Med. 2009 Jan 1;360(1):89-9019118315
Cites: Osteoporos Int. 2009 May;20(5):703-1418802659
Cites: Lancet. 2009 Apr 11;373(9671):1253-6319362675
Cites: Cochrane Database Syst Rev. 2009;(2):CD00714619370674
Cites: N Engl J Med. 2009 Apr 23;360(17):1789; author reply 1791-219387022
Cites: Calcif Tissue Int. 2009 Dec;85(6):484-9319823760
Cites: J Clin Endocrinol Metab. 2010 Mar;95(3):1174-8120080842
Cites: Breast. 2010 Apr;19(2):92-620079640
Cites: BMJ. 2010;341:c369120671013
Cites: JAMA. 2010 Aug 11;304(6):657-6320699457
Cites: BMJ. 2010;341:c444420813820
Cites: CMAJ. 2010 Sep 7;182(12):1315-920624865
Cites: J Bone Miner Res. 2010 Nov;25(11):2350-820499367
Cites: J Bone Miner Res. 2010 Nov;25(11):2267-9420842676
Cites: Osteoporos Int. 2011 Mar;22(3):839-4720959961
Cites: Osteoporos Int. 2011 Mar;22(3):829-3721161508
Cites: Osteoporos Int. 2011 Mar;22(3):817-2721161509
Cites: Osteoporos Int. 2011 Jun;22(6):1873-8320967422
Cites: Osteoporos Int. 2009 Dec;20(12):2111-2519421702
Cites: Endocr Rev. 2002 Aug;23(4):570-812202472
Cites: CMAJ. 2002 Nov 12;167(10 Suppl):S1-3412427685
Cites: Qual Saf Health Care. 2003 Feb;12(1):18-2312571340
Cites: JAMA. 2003 May 21;289(19):2525-3312759324
Cites: Arthritis Rheum. 2003 Nov;48(11):3224-914613287
Cites: J Bone Miner Res. 2004 Jun;19(6):893-915125788
Cites: BMC Musculoskelet Disord. 2004 Apr 6;5:1115068488
Cites: Bone. 2004 Aug;35(2):375-8215268886
Cites: JAMA. 1997 Feb 19;277(7):543-79032160
Cites: BMC Musculoskelet Disord. 2005;6:3916008835
Cites: Can Assoc Radiol J. 2005 Jun;56(3):178-8816144280
Cites: Osteoporos Int. 2005 Oct;16(10):1281-9015614441
Cites: J Clin Densitom. 2005 Winter;8(4):371-816311420
Cites: J Bone Joint Surg Am. 2006 Jan;88(1):25-3416391246
Cites: JAMA. 2006 Dec 27;296(24):2927-3817190893
Cites: Can Assoc Radiol J. 2007 Feb;58(1):27-3617408160
Cites: Osteoporos Int. 2007 Aug;18(8):1033-4617323110
Comment In: CMAJ. 2011 Apr 5;183(6):69521464177
Comment In: CMAJ. 2011 Apr 5;183(6):695-621464176
Comment In: CMAJ. 2010 Nov 23;182(17):1829-3020940235
PubMed ID
20940232 View in PubMed
Less detail

The A1330V polymorphism of the low-density lipoprotein receptor-related protein 5 gene (LRP5) associates with low peak bone mass in young healthy men.

https://arctichealth.org/en/permalink/ahliterature165637
Source
Bone. 2007 Apr;40(4):1006-12
Publication Type
Article
Date
Apr-2007
Author
Anne Saarinen
Ville-Valtteri Välimäki
Matti J Välimäki
Eliisa Löyttyniemi
Kirsi Auro
Piia Uusen
Mairi Kuris
Anna-Elina Lehesjoki
Outi Mäkitie
Author Affiliation
Folkhälsan Institute of Genetics and Department of Medical Genetics, University of Helsinki, Helsinki, Finland.
Source
Bone. 2007 Apr;40(4):1006-12
Date
Apr-2007
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Alleles
Bone Density - genetics
Calcifediol - blood
Finland
Fractures, Bone - etiology - genetics
Gene Frequency
Humans
LDL-Receptor Related Proteins - genetics
Low Density Lipoprotein Receptor-Related Protein-5
Male
Military Personnel
Osteoporosis - etiology - genetics
Parathyroid Hormone - blood
Polymorphism, Single Nucleotide
Risk factors
Abstract
Polymorphisms in the gene coding for low-density lipoprotein receptor-related protein 5 (LRP5) contribute to variation in bone mass in the general population. Whether this is due to influence on bone mass acquisition or on bone loss thereafter has not been established.
We studied the association of LRP5 polymorphisms with peak bone mass in young men. The study included 235 Finnish men, aged 18.3 to 20.6 years. Lifestyle factors and fracture history were recorded. Bone mineral content (BMC), density (BMD) and scan area were measured for the lumbar spine and proximal femur by dual energy X-ray absorptiometry (DXA). Blood and urine were collected for determination of bone turnover markers, serum 25-OHD and PTH. Genomic DNA was extracted from peripheral blood for genetic analysis of LRP5. Ten single nucleotide polymorphisms in LRP5 were analyzed and correlated with bone parameters.
Only the A1330V polymorphism of LRP5 significantly associated with bone parameters. In comparison with subjects with the AlaAla genotype (n=215), those with AlaVal genotype (n=20) had lower femoral neck BMC (P=0.029) and BMD (P=0.012), trochanter BMC (P=0.0067) and BMD (P=0.015), and total hip BMC (P=0.0044) and BMD (P=0.0089). Fracture history was similar for the genotypes.
The polymorphic valine variant at position 1330 of LRP5 was significantly associated with reduced BMC and BMD values in healthy young Finnish men. The results provide evidence for the crucial role of LRP5 in peak bone mass acquisition.
PubMed ID
17223614 View in PubMed
Less detail

Abdominal fat from spine dual-energy x-ray absorptiometry and risk for subsequent diabetes.

https://arctichealth.org/en/permalink/ahliterature144207
Source
J Clin Endocrinol Metab. 2010 Jul;95(7):3272-6
Publication Type
Article
Date
Jul-2010
Author
William D Leslie
Sora M Ludwig
Suzanne Morin
Author Affiliation
University of Manitoba, Winnipeg, Canada R2H 2A6. bleslie@sbgh.mb.ca
Source
J Clin Endocrinol Metab. 2010 Jul;95(7):3272-6
Date
Jul-2010
Language
English
Publication Type
Article
Keywords
Absorptiometry, Photon
Adult
Aged
Aged, 80 and over
Area Under Curve
Body Composition
Bone Density
Canada
Cohort Studies
Diabetes Mellitus, Type 2 - complications - diagnosis
Female
Health Surveys
Humans
Insulin Resistance
Middle Aged
Obesity, Abdominal - complications - diagnosis
Predictive value of tests
Risk factors
Abstract
Abdominal obesity is a major risk factor for diabetes. Dual-energy x-ray absorptiometry (DXA) of the lumbar spine provides an index of abdominal fat.
Our objective was to examine the hypothesis that DXA-derived abdominal fat measurement in women undergoing osteoporosis investigation predicts risk for subsequent diagnosis of diabetes.
This historical cohort study was derived from the Manitoba Bone Density Program Database for the Province of Manitoba, Canada.
30,252 nondiabetic women aged 40 yr and older were referred for baseline osteoporosis assessment with DXA between January 1990 and March 2007.
Each woman's longitudinal provincial health service record was assessed for the presence of diabetes diagnosis codes after DXA testing.
During 5.2 + or - 2.6 yr of observation, 1252 (4.1%) women met the case definition for diabetes. A greater proportion of abdominal fat from spine DXA was strongly related to subsequent diabetes diagnosis in models adjusted for age, body mass index, and other comorbidities. Those in the highest quintile had 3.56 (95% confidence interval = 2.67-4.75) times the risk for subsequent diabetes diagnosis compared with those in the lowest (reference) quintile. Fat from hip DXA was not predictive of subsequent diabetes after adjustment for the same variables (1.00, 95% confidence interval = 0.79-1.26).
Predictive information about diabetes risk can be obtained from spine DXA scans performed for osteoporosis risk assessment. This is consistent with evidence linking abdominal fat with insulin resistance and the metabolic syndrome.
PubMed ID
20392865 View in PubMed
Less detail

The ability of hand digital X-ray radiogrammetry to identify middle-aged and elderly women with reduced bone density, as assessed by femoral neck dual-energy X-ray absorptiometry.

https://arctichealth.org/en/permalink/ahliterature139761
Source
J Clin Densitom. 2010 Oct-Dec;13(4):418-25
Publication Type
Article
Author
Alvilde Dhainaut
Gudrun E Rohde
Unni Syversen
Villy Johnsen
Glenn Haugeberg
Author Affiliation
Department of Neuroscience, Rheumatology Division, INM Norwegian University of Science and Technology, Trondheim, Norway. alvilde.dhainaut@ntnu.no
Source
J Clin Densitom. 2010 Oct-Dec;13(4):418-25
Language
English
Publication Type
Article
Keywords
Absorptiometry, Photon - instrumentation
Aged
Area Under Curve
Bone Density
Case-Control Studies
Female
Femur Neck - radiography
Humans
Middle Aged
Norway - epidemiology
Osteoporosis - epidemiology - radiography
Quality of Life
Radius Fractures - epidemiology
Risk assessment
Statistics, nonparametric
Abstract
In this study, we evaluate the ability of digitized digital X-ray radiogrammetry (DXR) bone mineral density (BMD) to identify women with reduced BMD at femoral neck, assessed by dual-energy X-ray absorptiometry (DXA). The study population contained women with recent low-energy distal radius fracture and women recruited from the general population, all aged 50 yr or older. The correlation between hand BMD and femoral neck BMD was r=0.65 (p
PubMed ID
21029976 View in PubMed
Less detail

Absolute fracture risk reporting in clinical practice: a physician-centered survey.

https://arctichealth.org/en/permalink/ahliterature159036
Source
Osteoporos Int. 2008 Apr;19(4):459-63
Publication Type
Article
Date
Apr-2008
Author
W D Leslie
Author Affiliation
Department of Medicine, University of Manitoba, 409 Tache Avenue, Winnipeg R2H 2A6 Manitoba, Canada. bleslie@sbgh.mb.ca
Source
Osteoporos Int. 2008 Apr;19(4):459-63
Date
Apr-2008
Language
English
Publication Type
Article
Keywords
Absorptiometry, Photon
Bone Density - physiology
Data Collection - methods - statistics & numerical data
Female
Fractures, Bone - economics - prevention & control - radiography
Humans
Male
Manitoba
Osteoporosis - economics - physiopathology - radiotherapy
Physicians - statistics & numerical data
Professional Practice
Risk Assessment - economics - standards
Specialization - statistics & numerical data
Abstract
Non-expert clinical practitioners who had received bone density reports based on 10-year absolute fracture risk were surveyed to determine their response to this new system. Absolute fracture risk reporting was well received and was strongly preferred to traditional T-score-based reporting. Non-specialist physicians were particularly supportive of risk-based bone mineral density (BMD) reporting.
Absolute risk estimation is preferable to risk categorization based upon BMD alone. The objective of this study was to specifically assess the response of non-expert clinical practitioners to this approach.
In January 2006, the Province of Manitoba, Canada, started reporting 10-year osteoporotic fracture risks for patients aged 50 years and older based on the hip T-score, gender, age, and multiple clinical risk factors. In May 2006 and October 2006, a brief anonymous survey was sent to all physicians who had requested a BMD test during 2005 and 206 responses were received.
When asked whether the report contained the information needed to manage patients, the mean score for the absolute fracture risk report was higher than for the T-score-based report (p
PubMed ID
18239957 View in PubMed
Less detail

Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: an observational study.

https://arctichealth.org/en/permalink/ahliterature136584
Source
Scand J Urol Nephrol. 2011 Apr;45(3):196-205
Publication Type
Article
Date
Apr-2011
Author
Anders Fernström
Jan Giæver
Barbara Granroth
Britta Hylander
Gert Jensen
Anders Christensson
Björn Wikström
Lars Weiss
Ulf Wrege
Stefan H Jacobson
Author Affiliation
Department of Nephrology, Linköping University/Linköping University Hospital, Linköping, Sweden. anders.fernstrom@lio.se
Source
Scand J Urol Nephrol. 2011 Apr;45(3):196-205
Date
Apr-2011
Language
English
Publication Type
Article
Keywords
Aged
Biomarkers, Pharmacological - blood - metabolism
Bone Density - drug effects
Bone Density Conservation Agents - administration & dosage - pharmacology - therapeutic use
Bone Diseases, Metabolic - drug therapy - etiology - metabolism
Bone and Bones - metabolism
Calcium - blood
Chronic Disease
Ergocalciferols - administration & dosage - pharmacology - therapeutic use
Female
Humans
Hyperparathyroidism, Secondary - complications - drug therapy - metabolism
Injections, Intravenous
Kidney Diseases - complications - metabolism - therapy
Male
Middle Aged
Observation
Parathyroid Hormone - metabolism
Phosphorus - blood
Prospective Studies
Renal Dialysis
Sweden
Abstract
Secondary hyperparathyroidism (SHPT) is a common problem among patients with chronic kidney disease (CKD) on haemodialysis. This study was conducted to assess the use, effectiveness and safety of intravenous paricalcitol in haemodialysis patients with various degrees of SHPT.
This observational, multicentre, prospective study was conducted in 14 Swedish dialysis centres from May 2007 to June 2008 and included 92 haemodialysis patients with a diagnosis of SHPT associated with CKD. The decision to initiate treatment with intravenous paricalcitol was made by the treating physician. No treatment algorithms were provided.
Mean patient age was 64 years. Of the 92 patients included, 74 had an intact parathyroid hormone (iPTH) level of >300 pg/ml at baseline. Median iPTH was 584 pg/ml in patients with a baseline PTH of >300 pg/ml. During follow-up there was a decrease in iPTH to 323 pg/ml at 6 months (-45%, p
PubMed ID
21366390 View in PubMed
Less detail

993 records – page 1 of 100.